Amphastar subsidiary enters up to $1.5M supply deal with related party Letop Biotech

Amphastar Pharmaceuticals, Inc.

ANP subsidiary signed 3-year supply agreement with Nanjing Letop Biotechnology for chemical intermediates.
Total cost capped at ~$1.5M over 3 years; no minimum purchase obligation for ANP.
Henry Zhang, immediate family of CEO Jack Zhang and Chair Mary Luo, owns majority of Letop; deal was approved by independent Audit Committee members.
ANP retains ownership of all confidential information shared with Letop under the agreement.
Payments in Chinese yuan; price adjustments allowed once per 12 months with 2-month notice and customer consent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Amphastar Pharmaceuticals, Inc. entered into Agreement with Nanjing Letop Biotechnology Co., Ltd. valued at approximately $1.5 million (effective 2022-11-15).

Action: entry
Agreement: supply
Counterparty: Nanjing Letop Biotechnology Co., Ltd.
Value: approximately $1.5 million
Effective: 2022-11-15

Exact text from the filing

On November 15, 2022 (the “Effective Date”) Amphastar Nanjing Pharmaceuticals, Inc. (“ANP”), a wholly owned subsidiary of Amphastar Pharmaceuticals, Inc. (the “Company”), entered into a supply agreement (the “Agreement”) with Nanjing Letop Biotechnology Co., Ltd. (“Letop”).

View on SEC.gov

Browse all material agreements →

Amphastar Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001297184-22-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.